Bcli update - progress supports our 10x plus value range potential

Acf equity research  from acf equity research healthcare team london , july 24, 2024 /prnewswire/ --  nasdaq: bcli read acf equity research's update note here  read acf equity research's related thematic research note on regenerative medicine – neurodegenerative disease stem cells & als/mnd/lou gehrig's here update note: brainstorm cell therapeutics inc. (nasdaq: bcli) develops nurown® stem cell therapy for neurodegenerative diseases (ndds) – bcli's first target is als (mnd/lou gehrig's). since initiation – piiib rollout begins.
BCLI Ratings Summary
BCLI Quant Ranking